EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Progress on Topical Drug Therapy for Corneal Neovascularization

Xin-Can Huang, Guo-Yang Xu, Pei-Pei Yang, Lei Wang iD, Hao Wang, Ying Hu iD

ChemMedChem · 28.11.2025 · 20 (23)

DOI: 10.1002/cmdc.202500366 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 16.10.2025. Verfasst von Xin-Can Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Sha…. Hauptthemen laut MEDLINE: Corneal Neovascularization, Angiogenesis Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cornea is a crucial refractive medium in the visual system, characterized by its avascular and transparent nature under physiological conditions. Pathological factors such as ocular trauma and inflammation can induce the formation of new capillaries from the limbal vascular network, leading to corneal neovascularization (CNV). With an associated blindness rate as high as 12%, CNV has become a significant challenge in ophthalmology. Current treatment strategies for CNV primarily include drug therapy such as anti‐inflammatory and antiangiogenic agents, as well as surgical procedures like laser photocoagulation. These approaches are often limited by invasive procedures, suboptimal efficacy, and other constraints. Therefore, developing effective, safe, and convenient therapeutic options has become a critical research focus. Due to structural barriers of the ocular surface, the bioavailability of conventional eye drops is limited to ≈1%–5%, significantly restricting therapeutic efficacy. In recent years, researchers have been actively optimizing drug delivery systems using nanotechnology, hydrogels, and other advanced techniques to prolong ocular surface retention time, improve corneal penetration, and enhance drug release properties. This review summarizes recent advances in topical drug therapy for CNV, focusing on its pathogenesis, therapeutic agents, and delivery strategies, as well as approaches to enhance the bioavailability of topical treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Corneal NeovascularizationAngiogenesis InhibitorsHumansAnimalsAdministration, TopicalDrug Delivery Systems

Stichwörter der Autor:innen

bioavailabilitycorneal barriercorneal neovascularizationpro‐angiogenic factorstopical drug therapy

Substanzen

Angiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Shanghai, 200080, China.
  • CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 10019…

ORCID-Profile: Lei Wang, Ying Hu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, X. C., Xu, G. Y., Yang, P. P., Wang, L., Wang, H., & Hu, Y. (2025). Recent Progress on Topical Drug Therapy for Corneal Neovascularization. ChemMedChem, 20(23). https://doi.org/10.1002/cmdc.202500366

Vancouver

Huang XC, Xu GY, Yang PP, Wang L, Wang H, Hu Y. Recent Progress on Topical Drug Therapy for Corneal Neovascularization. ChemMedChem. 2025;20(23). doi:10.1002/cmdc.202500366

BibTeX
@article{Huang2025,
  author = {Huang, Xin-Can and Xu, Guo-Yang and Yang, Pei-Pei and Wang, Lei and Wang, Hao and Hu, Ying},
  title = {Recent Progress on Topical Drug Therapy for Corneal Neovascularization},
  journal = {ChemMedChem},
  year = {2025},
  volume = {20},
  number = {23},
  doi = {10.1002/cmdc.202500366}
}
Kostenlos starten →